pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2019-29-3-346-352pulmo-1178Research ArticleОБЗОРЫREVIEWКонтроль над бронхиальной астмой: актуальная проблема и ее решение в реальной клинической практикеAsthma control: actual problems and solutions in real clinical practiceЛещенкоИ. В.LeshchenkoI. V.

д. м. н., профессор кафедры фтизиатрии, пульмонологии и торакальной хирургии, 620028, Екатеринбург, ул. Репина, 3;

главный научный сотрудник, 620039, Свердловская область, Екатеринбург, ул. 22-го Партсъезда, 50;

научный руководитель клиники, 620109, Екатеринбург, ул. Заводская, 29

Doctor of Medicine, Professor, Department of Phthisiology, Pulmonology and Thoracic Surgery, ul. Repina 3, Ekaterinburg, 620028;

Chief Researcher, ul. 22-go Parts’ezda 50, Ekaterinburg, 620039;

Academic Advisor, ul. Zavodskaya 29, Ekaterinburg, 620109

leshchenkoiv@mail.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Уральский научно-исследовательский институт фтизиопульмонологии – филиал Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» Министерства здравоохранения Российской Федерации; Общество с ограниченной ответственностью «Медицинское объединение "Новая больница"»РоссияUral Federal State Medical University, Healthcare Ministry of Russia; Ural Federal Research Institute of Phthisiology and Pulmonology – A Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia; “Novaya bol’nitsa” Clinical Association LLCRussian Federation201917082019293346352Copyright © Лещенко И.В., 20192019Лещенко И.В.Leshchenko I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1178

Достижение контроля над бронхиальной астмой (БА) остается труднодостижимой целью. Одним из основных инструментов для оценки контроля над БА является известный тест по контролю над БА (Asthma Control Test – ACT). К основным причинам отсутствия контроля над БА относится низкая приверженность лечению и несоблюдение пациентом режима дозирования. Правильная техника ингаляций способствует повышению приверженности лечению. Порошковый ингалятор Эллипта – один из немногих многодозовых ингаляторов, оснащенный счетчиком доз с индикатором числа оставшихся доз и устройством активации доз одним движением. Основная роль в базисной медикаментозной терапии принадлежит ингаляционным глюкокортикостероидам (иГКС) и длительно действующим β2-агонистам (ДДБА). Современная комбинация вилантерол / флутиказона фуроат (ВИ / ФФ) является высокоэффективным базисным препаратом для лечения больных БА средней и тяжелой степени; 24-часовое действие препарата позволяет применять его 1 раз в сутки. Преимущество применения комбинации ВИ / ФФ по сравнению с монотерапией иГКС и комбинаций других иГКС / ДДБА в реальной клинической практике у больных БА, независимо от тяжести заболевания и сопутствующих заболеваний, подтверждено результатами Солфордского исследования.

Asthma control is still difficult to achieve. One of main tools for evaluating asthma control is a well-known Asthma Control Test (ACT). Common causes of insufficient asthma control include poor adherence to treatment and non-compliance of the patient with the dosing regimen. Correct inhalation technique significantly contributes to better adherence to treatment. Elliptа is a multi-dose powder inhaler with dose counter and indication of remaining dose number. Actuation of Ellipta inhaler requires only one movement. Inhaled glucocorticosteroids (ICS) and long-acting β2-agonists (LABA) are the key agents in the maintenance pharmacological therapy of asthma. A novel vilanterol/fluticasone furoate (VI/FF) combination is a highly effective combination for maintenance treatment of moderate to severe asthma with 24-hour effect providing once-daily dosing. The Salford study demonstrated advantages of VI/FF combination over ICS monotherapy and other combination of ICS/LABA in real clinical practice in patients with asthma out of dependence of asthma severity or comorbidities.

бронхиальная астмаконтроль над бронхиальной астмойингаляционные глюкокортикостероидыдлительно действующие β2-агонистывилантеролфлутиказона фуроатЭллиптаbronchial asthmaasthma controlinhaled corticosteroidslong-acting β2-agonistsvilanterolfluticasone furoateElliptaСтатья подготовлена при поддержке компании ЗАО «Глаксо Смит Кляйн Трейдинг» (Россия) в соответствии с действующим законодательством Российской Федерации и принципами Добросовестной практики научных публикаций (Good Publication Practice).This publication is supported by ZAO “GlaxoSmithKline Traiding”, Russia, according to the current legislation of Russian Federation and Good Publication Practice standards.ReferencesRabe K.F., Vermeire P.A., Soriano J.B., Maier W.C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000; 16 (5): 802–807.Rabe K.F., Vermeire P.A., Soriano J.B., Maier W.C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000; 16 (5): 802–807.Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2018. Available at: https://ginasthma.org/wp-content/uploads/2018/03/WMSFINAL-GINA-2018-Appendix_v1.3.pdfGlobal Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2018. Available at: https://ginasthma.org/wp-content/uploads/2018/03/WMSFINAL-GINA-2018-Appendix_v1.3.pdfPartridge M.R., van der Molen T., Myrseth S.E., Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm. Med. 2006; 9: 13. DOI: 10.1186/1471-2466-6-13.Partridge M.R., van der Molen T., Myrseth S.E., Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm. Med. 2006; 9: 13. DOI: 10.1186/1471-2466-6-13.Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur. Respir. Rev. 2012; 21 (123): 66–74. DOI: 10.1183/09059180.00008111.Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur. Respir. Rev. 2012; 21 (123): 66–74. DOI: 10.1183/09059180.00008111.Iwanaga T., Kumar, M., Goren, A. et al. Cross sectional patient – reported survey on asthma control and associated burdens in Japanese patients with asthma in 2013. Ther. Res. 2015; 36 (3): 235–246.Iwanaga T., Kumar, M., Goren, A. et al. Cross sectional patient – reported survey on asthma control and associated burdens in Japanese patients with asthma in 2013. Ther. Res. 2015; 36 (3): 235–246.FitzGerald J.M., Boulet L.P., McIvor R.A. et al. Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study. Can. Respir. J. 2006; 13 (5): 253–259. DOI: 10.1155/2006/753083.FitzGerald J.M., Boulet L.P., McIvor R.A. et al. Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study. Can. Respir. J. 2006; 13 (5): 253–259. DOI: 10.1155/2006/753083.Mintz M., Gilsenan A.W., Bui C.L. et al. Assessment of asthma control in primary care. Curr. Med. Res. Opin. 2009; 25 (10): 2523–2531. DOI: 10.1185/03007990903218655.Mintz M., Gilsenan A.W., Bui C.L. et al. Assessment of asthma control in primary care. Curr. Med. Res. Opin. 2009; 25 (10): 2523–2531. DOI: 10.1185/03007990903218655.Price D., Fletcher M., van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim. Care. Respir. Med. 2014; 24: 14009. DOI: 10.1038/npjpcrm.2014.9.Price D., Fletcher M., van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim. Care. Respir. Med. 2014; 24: 14009. DOI: 10.1038/npjpcrm.2014.9.Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011; (6): 87–93. DOI: 10.18093/0869-0189-2011-0-6-87-93.Arkhipov V.V., Grigoryeva E.V., Gavrishina E.V. [A control of bronchial asthma in Russia: results of NIKA multi-center observational study]. Pul'monologiya. 2011; (6): 87–93. DOI: 10.18093/0869-0189-2011-0-6-87-93 (in Russian).Haughney J., Price D., Kaplan A. et al Achieving asthma control in practice: anderstanding the reasons of poor control. Respir. Med. 2008; 102 (12): 1681–1693. DOI: 10.1016/j.rmed.2008.08.003.Haughney J., Price D., Kaplan A. et al Achieving asthma control in practice: anderstanding the reasons of poor control. Respir. Med. 2008; 102 (12): 1681–1693. DOI: 10.1016/j.rmed.2008.08.003.Nose M., Barbui C., Gray R., Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br. J. Psychiatry. 2003; 183 (3):197–206. DOI: 10.1192/bjp.183. 3.197.Nose M., Barbui C., Gray R., Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br. J. Psychiatry. 2003; 183 (3):197–206. DOI: 10.1192/bjp.183. 3.197.Petrie K.J., Perry K., Broadbent E., Weinman J. A text message programme designed to modify patients' illness and treatment beliefs improves self-reported adherence to asthma preventer medication. Br. J. Health Psychol. 2012; 17 (1): 74–84. DOI: 10.1111/j.2044-8287.2011.02033.x.Petrie K.J., Perry K., Broadbent E., Weinman J. A text message programme designed to modify patients' illness and treatment beliefs improves self-reported adherence to asthma preventer medication. Br. J. Health Psychol. 2012; 17 (1): 74–84. DOI: 10.1111/j.2044-8287.2011.02033.x.Grant A.C., Walker R., Hamilton M., Garrill K. The ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J. Aerosol Med. Pulm. Drug Deliv. 2015; 28 (6): 474–485. DOI: 10.1089/jamp.2015.1223.Grant A.C., Walker R., Hamilton M., Garrill K. The ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J. Aerosol Med. Pulm. Drug Deliv. 2015; 28 (6): 474–485. DOI: 10.1089/jamp.2015.1223.Asthma Control Test. Available at: http://www.asthma.com/additional-resources/asthma-control-test.htmlAsthma Control Test. Available at: http://www.asthma.com/additional-resources/asthma-control-test.htmlThomas M., Kay S., Pike J. et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim. Care Respir. J. 2009; 18 (1): 41–49. DOI: 10.4104/pcrj.2009. 00010.Thomas M., Kay S., Pike J. et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim. Care Respir. J. 2009; 18 (1): 41–49. DOI: 10.4104/pcrj.2009. 00010.O’Byrne P.M., Reddel H.K., Eriksson G. et al. Measuring asthma control: a comparison of three classification systems. Eur. Respir. J. 2010; 36 (2): 269–276. DOI: 10.1183/09031936.00124009.O’Byrne P.M., Reddel H.K., Eriksson G. et al. Measuring asthma control: a comparison of three classification systems. Eur. Respir. J. 2010; 36 (2): 269–276. DOI: 10.1183/09031936.00124009.Ko F.W., Hui D.S., Leung T.F. et al. Evaluation of the asthma control test: a reliable determinant of disease stability and a predictor of future exacerbations. Respirology. 2012; 17 (2): 370– 378. DOI: 10.1111/j.1440-1843.2011.02105.x.Ko F.W., Hui D.S., Leung T.F. et al. Evaluation of the asthma control test: a reliable determinant of disease stability and a predictor of future exacerbations. Respirology. 2012; 17 (2): 370– 378. DOI: 10.1111/j.1440-1843.2011.02105.x.Valotis A., Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir. Res. 2007; 8: 54–62. DOI: 10.1186/1465-9921-8-54.Valotis A., Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir. Res. 2007; 8: 54–62. DOI: 10.1186/1465-9921-8-54.Slack R.J., Barrett V.J. Morrison V.S. et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J. Pharmacol. Exp. Ther. 2013; 344 (1): 218–230. DOI: 10.1124/ jpet.112.198481.Slack R.J., Barrett V.J. Morrison V.S. et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J. Pharmacol. Exp. Ther. 2013; 344 (1): 218–230. DOI: 10.1124/ jpet.112.198481.New J.P., Bakerly N.D., Leather D., Woodcock A. Obtaining real-world evidence: the Salford Lung Study. Thorax. 2014; 69 (12): 1152–1154. DOI: 10.1136/thoraxjnl-2014-205259.New J.P., Bakerly N.D., Leather D., Woodcock A. Obtaining real-world evidence: the Salford Lung Study. Thorax. 2014; 69 (12): 1152–1154. DOI: 10.1136/thoraxjnl-2014-205259.Vestbo J., Leather D., Bakerly N.D. et al. Effectiveness of fluticasone furoate–vilanterol for COPD in clinical practice. N. Engl. J. Med. 2016; 375 (13): 1253–1260. DOI: 10.1056/NEJMoa1608033.Vestbo J., Leather D., Bakerly N.D. et al. Effectiveness of fluticasone furoate–vilanterol for COPD in clinical practice. N. Engl. J. Med. 2016; 375 (13): 1253–1260. DOI: 10.1056/NEJMoa1608033.Woodcock A., Vestbo J., Bakerly N.D. et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open label, parallel group, and randomized controlled trial. Lancet. 2017; 390 (10109): 2247–2255. DOI: 10. 1016/S0140-6736(17)32397-8.Woodcock A., Vestbo J., Bakerly N.D. et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open label, parallel group, and randomized controlled trial. Lancet. 2017; 390 (10109): 2247–2255. DOI: 10. 1016/S0140-6736(17)32397-8.Schatz M., Sorkness C.A., Li J.T. et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J. Allergy Clin. Immunol. 2006; 117 (3): 549–556. DOI: 10.1016/j.jaci.2006.01.011.Schatz M., Sorkness C.A., Li J.T. et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J. Allergy Clin. Immunol. 2006; 117 (3): 549–556. DOI: 10.1016/j.jaci.2006.01.011.Svedsater H., Jones R., Bosanquet N. et al. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. Respir. Med. 2018; 141: 198–206. DOI: DOI: 10.1016/j.rmed.2018.06.003.Svedsater H., Jones R., Bosanquet N. et al. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. Respir. Med. 2018; 141: 198–206. DOI: DOI: 10.1016/j.rmed.2018.06.003.Marks G.B., Dunn S.M., Woolcock A.J. An evaluation of an asthma quality of life questionnaire as a measure of change in adults with asthma. J. Clin. Epidemiol. 1993; 46 (10): 1103–1111.Marks G.B., Dunn S.M., Woolcock A.J. An evaluation of an asthma quality of life questionnaire as a measure of change in adults with asthma. J. Clin. Epidemiol. 1993; 46 (10): 1103–1111.Juniper E.F., Buist A.S., Cox F.M. et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999; 115 (5): 1265–1270. DOI: 10.1378/chest.115.5.1265.Juniper E.F., Buist A.S., Cox F.M. et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999; 115 (5): 1265–1270. DOI: 10.1378/chest.115.5.1265.Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993; 4 (5): 353– 365. DOI: 10.2165/00019053-199304050-00006.Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993; 4 (5): 353– 365. DOI: 10.2165/00019053-199304050-00006.EQ-5D® Is a Standardized Instrument for as a Measure of Health Outcome. EQ-5D Instrument. EuroQol 5-Dimensions 3-Levels Questionnaire, EQ-5D-3L. Avail able at: https://euroqol.org/EQ-5D® Is a Standardized Instrument for as a Measure of Health Outcome. EQ-5D Instrument. EuroQol 5-Dimensions 3-Levels Questionnaire, EQ-5D-3L. Avail able at: https://euroqol.org/Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2019. Available at: http://www.ginasthma.org/Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2019. Available at: http://www.ginasthma.org/

The authors declare that there are no conflicts of interest present.